<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930318</url>
  </required_header>
  <id_info>
    <org_study_id>PTP-IR-EEN-1</org_study_id>
    <nct_id>NCT01930318</nct_id>
  </id_info>
  <brief_title>Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery</brief_title>
  <official_title>Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance, Tramadol PCA and Early Postoperative Enteral Nutrition in Patients After Gastrointestinal Laparoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinling Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jinling Hospital, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well established that the resistance to the effects of insulin on glucose metabolism
      develops with a lot of stress hormone release after surgical trauma. This condition is known
      as insulin resistance (IR) characterized by hyperglycemia, hyperinsulinemia and lactic
      acidosis. Surgical IR not only affect glucose metabolism but also influence protein
      synthesis, then further exacerbate the depletion of the carbohydrate, fat and protein.

      Postoperative pain is a challenging task for patients and surgeons, and it is part of the
      stress response to trauma and surgery, while the fear of pain can exacerbate the stress
      response.

      The main aim of this study was to invest whether effective postoperative analgesia can reduce
      the stress response and insulin resistance.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin resistance in perioperative period of gastrointestinal laparoscopic surgery</measure>
    <time_frame>5 days after operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The consumption of total and incremental tramadol after surgery.</measure>
    <time_frame>5 days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The tolerated dose of enteral nutrition every day after surgery</measure>
    <time_frame>5 days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative inflammatory factors (IL-4, IL-6 and TNF-α) and levels of stress hormone (glucocorticoids and catecholamines) in perioperative period of gastrointestinal laparoscopic surgery</measure>
    <time_frame>5 days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rest energy metabolism was measured in perioperative period to evaluate the caloric and substrate needs of our patients</measure>
    <time_frame>5 days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time of the first bowel movements and anal exhaust time after surgery</measure>
    <time_frame>5 days after operation or more</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity at rest and during leg raising recorded daily after surgery using Visible Numeric Rating Scale</measure>
    <time_frame>5 days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events throughout the treatment period including nausea, vomiting, headache, urinary retention, somnolence, flatulence, and pruritus</measure>
    <time_frame>5 days after operation or more</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver and renal function tests in perioperative period</measure>
    <time_frame>5 days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating anxiety scale and self-rating questionnaire for depression before surgery</measure>
    <time_frame>1 day before surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Gastrointestinal Cancer</condition>
  <arm_group>
    <arm_group_label>PCA,Placebo,Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCA,placebo,tramadol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol in the day 3 to day 5 after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCA,parecoxib,placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCA for 2 days after operation, i.v parecoxib in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCA,parecoxib,celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCA for 2 days after operation,i.v parecoxib in 2 days after surgery and oral celecoxib in the day 3 to day 5 after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>parecoxib</intervention_name>
    <description>4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery</description>
    <arm_group_label>PCA,parecoxib,placebo</arm_group_label>
    <arm_group_label>PCA,parecoxib,celecoxib</arm_group_label>
    <other_name>COX-2 selective inhibitors</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with gastrointestinal cancer scheduled for gastrointestinal laparoscopic
             surgery

          -  Patients between the ages of 18 and 70 yr

          -  ASA physical status I-II

          -  Requirements of informed consent and assent of participant, parent or legal guardian
             as applicable

          -  Consciousness and ability to cooperate

        Exclusion criteria：

          -  History of alcohol, analgesic, or narcotic abuse

          -  Used analgesics, neuroleptics, antipsychotic agents, or corticosteroids within 6 hours
             of surgery

          -  A clinically significant laboratory abnormality or a history of significant cardiac,
             pulmonary, hepatic, or renal disease

          -  Female with positive pregnancy

          -  Allergy to conventional NSAIDs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wencheng Kong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wengcheng Kong, MD</last_name>
    <phone>15850722032</phone>
    <email>wenchengkong@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yousheng Li</last_name>
    <phone>8602580860137</phone>
    <email>liys@medmail.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>200002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wencheng Kong, MD</last_name>
      <phone>15850722032</phone>
      <email>wenchengkong@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yousheng Li, MD</last_name>
      <email>liys@medmail.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Wencheng Kong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danhua Yao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>lele Ren, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xu Z, Li Y, Wang J, Li J. Effect of postoperative analgesia on energy metabolism and role of cyclooxygenase-2 inhibitors for postoperative pain management after abdominal surgery in adults. Clin J Pain. 2013 Jul;29(7):570-6. doi: 10.1097/AJP.0b013e318270f97b.</citation>
    <PMID>23328338</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <last_update_submitted>November 7, 2014</last_update_submitted>
  <last_update_submitted_qc>November 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinling Hospital, China</investigator_affiliation>
    <investigator_full_name>Kong Wencheng</investigator_full_name>
    <investigator_title>Senior Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Parecoxib</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

